Profile

Cover photo
Advaxis, Inc.
30 followers|15,140 views
AboutPostsPhotosYouTube

Stream

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has released a letter to shareholders from President and CEO Dan O’Connor. Read the full letter here: http://bit.ly/1TaG3Cv
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
We are pleased to announce that Daniel J. O’Connor, President and Chief Executive Officer of Advaxis, has been appointed to the Board of Trustees of BioNJ. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has appointed Dr. Bradley Monk as lead cervical cancer advisor. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has provided a 2016 business outlook, intended to provide investors with an overview of anticipated events and key milestones for the coming year. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
We are pleased to announce that the FDA has lifted Advaxis’s clinical hold. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis to present poster on ADXS-HER2 at the 2015 San Antonio Breast Cancer Symposium (SABCS) today, December 9. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Data from Stage 1 of a Phase 2 study of axalimogene filolisbac in cervical cancer, conducted by Gynecologic Oncology Group, were featured in a recent review article in Clinical Therapeutics. Find the full journal article here: http://bit.ly/1kQtwHJ
1
Add a comment...
Have them in circles
30 people
Bill Stuart's profile photo
yolande lorijn's profile photo
Scott A's profile photo
Shon Booker's profile photo
Christina Kindborg's profile photo
Rick Vandewaa's profile photo
Liz Peters's profile photo
David Miller's profile photo
Michael Higgins's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Advaxis' axalimogene filolisbac to be developed and commercialized in Latin America With Stendhal. Twenty countries in Latin America and the Caribbean will be covered by the Agreement. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
We are pleased to announce Advaxis has expanded its Intellectual Property for its Lm Technology™ Platform. The company today announced that it has added two more patents to its growing patent portfolio. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has established a Scientific Advisory Board with several distinguished experts. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis receives Orphan Drug Designation in the European Union for axalimogene filolisbac for the treatment of anal cancer. See the full announcement here:
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis receives Orphan Drug Designation in the European Union for ADXS-HER2 for the treatment of osteosarcoma. See the full announcement here:
1
Add a comment...
People
Have them in circles
30 people
Bill Stuart's profile photo
yolande lorijn's profile photo
Scott A's profile photo
Shon Booker's profile photo
Christina Kindborg's profile photo
Rick Vandewaa's profile photo
Liz Peters's profile photo
David Miller's profile photo
Michael Higgins's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.